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Multiple sclerosis (MS) is characterized by inﬂammation, axonal and oligodendrocyte pathology and
progressive neurological disability. Epidemiologic data indicate that MS may be caused by interplay
of genetic and environmental factors. Large samples collected in cooperative efforts and new tech-
nologies such as high throughput single nucleotide polymorphism (SNP) genotyping allowed
recently to discover non-HLA genes associated with MS susceptibility that are mostly involved in
the immune response. In addition, several studies indicate an effect of genetic variations on disease
onset, progression and response to therapy. However, the polymorphisms discovered so far explain
the genetic variation in MS only in part and are mostly common variants that have only low impact
on MS susceptibility. Functional studies are required to validate the importance of the newly iden-
tiﬁed SNPs. Taking into account the interplay of genetic and environmental factors a combination of
genome wide genotyping including HLA-typing and genome wide expression proﬁling as well as a
collection on relevant or putatively relevant environmental factors in patients well characterized
clinically and by MRI is a promising way to identify new disease relevant biomarkers.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
In Europeans and their descendants MS is the most common
disease that affects the central nervous system (CNS) in young
adults and leads to progressive disability [1]. Histopathologically
MS is characterized by inﬁltrating inﬂammatory cells (lympho-
cytes, macrophages) leading to recurrent inﬂammation in brain
and spinal cord. In particular during later disease stages inﬂamma-
tion declines, but demyelination and axonal loss proceed and lead
to increasing disability [2]. Typically MS starts with relapses and
remissions and develops over time into a progressive disease. Only
a minority of patients starts with a primary progressive form just
from the beginning [3]. By strong circumstantial evidence MS is
supposed to be an autoimmune disease [4]. However, the cause
of the disease and its pathophysiology are not understood in detail.
It is not a heritable disease in the classic sense, but a genetic pre-
disposition in combination with environmental risk factors such
as place and season of birth, distance to the equator, infections in
childhood and vitamin D deﬁciency seems to induce the disease
(Fig. 1). The risk of MS is increased in ﬁrst-degree relatives (sib-
lings, 5%; parents and children, 2%) and 1% in second-degree and
third-degree relatives [5]. These data strongly support a genetic
impact on MS susceptibility. So far several genes have been identi-cal Societies. Published by Elsevier
ory Disorders of the CNS,
raepelinstrasse 2-10, 80804
er).ﬁed to be involved in disease susceptibility that have mostly func-
tions in the immune system encouraging the hypothesis of an
underlying autoimmune process.2. HLA genes
In the 1970s, linkage analysis revealed different variations in
HLA loci affecting the risk of MS [6–8]. The ﬁrst loci discovered
in these studies were within the HLA-A3 and HLA-B7 genes and in-
creased the risk to develop MS. A few years later an association of
HLA class II genes, i.e., HLA-DR2 and -DR3 with MS susceptibility
was demonstrated [9]. The HLA class II loci DQA1, DQB1, DRB1,
and DPB1 were analyzed in the early 1990s in Scandinavian popu-
lations revealing a strong effect of HLA-DRB1 followed by HLA-
DQB1 and less pronounced effects of HLA-DPB1 and HLA-DQA1
[10–12]. Over the last two decades these MS susceptibility loci
within the HLA region on chromosome 6 were replicated in several
populations. HLA-DRB1 (DR15, DQ6, Dw2, i.e., the DRB11501-
DQA10102-DQB10602 haplotype) has still the best evidence for
association with MS. An independent, additional effect of HLA class
I loci HLA-A3 (HLA-A0301) doubling the risk for MS has been re-
cently reported [13]. On the other hand there are protective effects
with respect to disease susceptibility of the HLA class I loci HLA-A2
(HLA-A0201) and HLA-C05 [14,15]. The inﬂuence of both HLA
class I and class II genes on MS susceptibility may reﬂect the
important roles of HLA class I dependent CD8+ T-cells and HLA
class II reliant CD4+ T-cells in the pathophysiology of MS [16].B.V. Open access under CC BY-NC-ND license.
Fig. 1. MS: An interplay between genes and environment.
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ease susceptibility, but also on disease course. An effect of HLA-
DRB115 on the age of onset has been described and replicated
[17]. In contrast HLA-A3 did not inﬂuence the age of onset in a
Scandinavian study [18]. There are hints that the severity of dis-
ease determined by MRI parameters is affected by HLA genes,
too. In a recent study HLA-B44 positive patients, especially if
HLA-DRB11501 negative, are characterized by lower brain atro-
phy and T2-lesion volume. In the presence of HLA-DRB11501,
however, HLA-DRB110 was protective, but HLA-DRB104 and
HLA-DRB114 were associated with higher T2-lesion volume
[19]. In contrast, an Australian study did not detect any inﬂuence
of HLA-DRB1 on disease severity, brain atrophy or cognition [20].
In summary, the effect of HLA on disease course is much less inves-
tigated than its impact on susceptibility.
Recently an environment gene interaction has been demon-
strated for HLA-DRB115 and vitamin D. The vitamin D receptor
inﬂuences the rate of transcription of vitamin D responsive genes
by binding to vitamin D response elements. A vitamin D response
element in the HLA-DRB1 promoter region showed haplotype spe-
ciﬁc differences, being highly conserved in the DR2 haplotype
bearing the HLA-DRB115 allele, but not conserved generally.
Transient transfection of B cells with the HLA-DRB115 gene pro-
moter leads to increased expression on stimulation with 1,25-
dihydroxyvitamin D3 [21].
3. Identiﬁcation of non-HLA genes
HLA association explains only a part of the genetic impact on dis-
ease susceptibility, but for almost three decades the inﬂuence of
non-HLA genes remained elusive. Linkage analysis in affected fam-
ilies highlighted the interleukin-2 receptor gene (IL2R) and inter-
leukin-7 receptor gene (IL7R) regions, but failed to conﬁrm an
association [22,23]. Because of the small individual contribution
of each gene, the identiﬁcation and validation of non-HLA suscepti-
bility genes did not succeed even in a more powerful linkage scan,
in which 4506 single nucleotide polymorphisms (SNPs) in 2692
samples from 730 multiplex families were analyzed [24,25]. There-
fore new methods, namely genome wide association studies in
combination with high throughput SNP genotyping, were needed
to query comprehensive effects of more common genetic variants.
Association studies have a greater statistical power than linkage
studies to detect common genetic variants with a small effect on
disease susceptibility. A large scale genome wide association study
was applied ﬁrst in 2007 to detect non-HLA genes conferring risk
to MS and revealed in a replication step a signiﬁcant association
of the alpha chain of the interleukin-2 receptor gene (IL2RA) and
of the interleukin-7 receptor gene (IL7RA) with MS [24]. Although
not signiﬁcant, there was evidence for a possible association of the
following genes with MS susceptibility in this study: C-type lectin
domain family 16 member A (CLEC16A) (formerly known as
KIAA0350), RPL5, DBC1, CD58, ALK, FAM69A, ANKRD15, EVI5,
KLRB1, CBLB and PDE4B [24]. In 2005 a candidate approach had al-ready revealed an association of IL7RA and LAG3 with MS. LAG3
and IL7R were chosen for the study on the basis of their location
in regions linked to autoimmune diseases [26]. A link between
chromosome 12p13 and 5p13 and MS had been previously de-
scribed [22]. A role of LAG3 in MS susceptibility could not be repro-
duced so far [27]. A summary of newly identiﬁed non-HLA MS
susceptibility genes is given in Table 1. Most of the identiﬁed genes
are involved in maintenance of the immune response and several
of them are also associated with other autoimmune disease like
rheumatoid arthritis (CLEC16A, IL2RA, IL7RA, IRF5) or type I diabe-
tes mellitus (CLEC16A, IL2RA, CD226) supporting the autoimmune
hypothesis of MS aetiology [28–31]. However, two genes are in-
volved in neuronal repair and the function of some genes is un-
known. In the following a selection of probably relevant genes is
discussed in more detail.
4. Genes involved in T cell regulation
The effect of IL7RA and IL2RA genes, coding for the alpha chain
of the IL-7 or IL-2 receptors that are important in promoting the
growth and differentiation of lymphocytes has been conﬁrmed in
several MS populations [32–36]. Both IL-7 and IL-2 are gamma
chain cytokines with their main function in T-cell homeostasis
which is impaired in MS. CD58 and CD6 have selective effects on
protective regulatory T cells, respectively, Th17 cells that cause
inﬂammatory lesions in MS. Therefore the putative roles of these
interesting genes is described in the following in more detail.
4.1. IL-7RA
The inﬂuence of rs6897932 within exon 6 of the IL7RA gene on
MS susceptibility is meanwhile replicated in a number of studies
[36]. The IL-7/IL7RA interaction is important for the maintenance
of memory T cells and the development, proliferation and survival
of B and T cells, especially cd+ T cells, which are present in inﬂam-
matory lesions of MS patients [37,38]. The protective haplotype
reduces splicing of exon 6, leading to less production of soluble
IL-7Ra. This is of importance, as activation of the IL-7/IL-7R inter-
action depends on the expression level of the receptor without a
known mechanism for up-regulating its ligand [36]. Moreover,
the soluble IL-7 receptor alpha chain was shown recently to inhibit
IL-7 activity in CD8+ T cells [39].
4.2. IL2RA
Two SNPs rs12722489 and rs2104286 within the IL2RA gene
were identiﬁed and conﬁrmed to confer MS susceptibility. Both
variants were typed in an additional 20 708 individuals in
Australia, Belgium, Denmark, Finland, France, Germany, Ireland,
Italy, the Netherlands, Norway, Sardinia, Spain, Sweden, and new
samples from the UK. Conditioning on each marker demonstrates
that the association seen at rs12722489 is a consequence of its
linkage disequilibrium with rs2104286. This ﬁnding conﬁrms that
rs2104286 – or another SNP in linkage disequilibrium with it – is
the primary association. Interestingly, rs2104286 showed less sig-
niﬁcant association than rs12722489 in the original screen. Testing
for association at the genotypic level conﬁrms that the homozy-
gous risk genotype confers a signiﬁcantly greater risk than the het-
erozygous genotype for both rs6897932 and rs2104286 [40].
Although the odds ratios implicate only a moderate effect, this
gene has important functional relevance in autoimmunity. IL-2
(formerly known as T-cell growth factor) is essential for prolifera-
tion of antigen-activated T cells. The IL-2 receptor alpha chain also
known as CD25 is highly expressed in activated T cells, but also in
regulatory T cells and allows a reaction to small amounts of IL-2
Table 1
Non-HLA genes conferring MS susceptibility.
Gene Best associated SNPs Risk allele OR P-value Main function References
IL7RA rs6897932 T 0.82 7.0  1010 Proliferation of (memory) T cells [36]
IL2RA (CD25) rs2104286 C 1.17 2.2  104 Sensitization of activated T cells to IL-2
mediated proliferation
[34]
rs12722489 T 1.33 3.5  102 [34]
PRKCA Allelic variant between
introns 3 and 8
1.64 Regulation of IL-2 and the IL-2 receptor
expression
[44]
CD58 rs2300747 G 0.82 1.1  106 Improvement of function regulatory T cells [47]
CD6 rs17824933 C 1.18 3.8  109 Regulation and adhesion of Th17 and other T
cells
[50]
CLEC16A rs6498169 G 1.14 3.8  106 Pattern recognition receptor, induction of
immune response
[24]
rs12708716 A 1.20 1.6  1016 [28]
VAV1 rs2546133-rs2617822 CA 1.18 2.0  105 Survival, proliferation and differentiation of
lymphocytes
[58]
EVI5 rs6680578 T 1.23 8.2  103 Vesicular trafﬁcking, cytokinesis and cell-cycle
control, nuclear zinc ﬁnger protein
[111–114]
IRF5 rs4728142 A 1.14 1.0  103 Regulation of the toll-like receptor dependent
activation of inﬂammatory cytokines
[115]
rs3807306 A 1.14 2.0  103 [115]
IRF8 rs17445836 A 0.80 3.7  109 Expression of IFN-response pathway genes, B
cell germinal center development
[50]
TYK2 rs34536443 G 0.77 5.1  109 JAK kinase enhancing expression of IFN-
regulated genes, involved in different cytokine
pathways
[72–75]
TNFRSF1 rs1800693 T 1.20 1.6  1011 Tumor necrosis factor receptor [50]
rs4149584 C 1.58 5.3  106 [50]
CD40
(TNFRSF5)
rs1883832 T 1.12 2.5  102 Tumor necrosis factor receptor [65]
CD226 rs763361 T 1.13 5.4  108 Activation on natural killer cells, costimulator
on T cells, facilitates endothelial
transmigration
[28,116–119]
CYP27B1 rs703842 A 0.83 5.1  1011 Vitamin D metabolism [120]
KIF1B rs10492972 C 1.35 2.5  1010 Neuronal regeneration [80]
GPC 5 rs9523762 G 1.23 1.6  105 Neuronal growth and repair [85]
For each gene OR and P-values were selected from one reference.
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type showed a reduction of CD25 expression by stimulated CD14+
CD16+ monocytes and CD4+ naïve T cells – thereby reducing the
likelihood of activation. With respect to T cell activation this geno-
typic effect lead to a lower proportion of CD69+ CD4+ naïve T cells
upregulating CD25. However, there was no effect of rs2104286 on
the CD4+ memory T-cell phenotype – in contrast to another SNP
(minor allele G at rs12722495) that is protective to diabetes melli-
tus [42]. The importance of IL-2 biology in MS susceptibility is sup-
ported by the involvement of the protein kinase C alpha gene
(PRKCA) that inﬂuences T-cell receptor/CD28-induced IL-2 gene
expression and the regulation of IL-2 receptor expression [43–45].
4.3. CD58
A dysfunction of regulatory T cells leading to a lack of suppres-
sion of autoaggressive T cells has been shown in MS patients [46].
CD58 overexpression up-regulates the expression of transcription
factor FoxP3 through engagement of the CD58 receptor improving
the function of CD4(+)CD25(high) regulatory T cells [47].
Rs2300747 within the CD58 gene was found associated with MS
and was replicated in several populations [24,31,48,49]. The pro-
tective G allele is associated with a dose-dependent increase in
CD58 mRNA expression in lymphoblastic cell lines and in periphe-
ral blood mononuclear cells from MS subjects. As CD58 mRNA
expression is higher in MS patients during clinical remission, en-
hanced expression of CD58 may have a protective effect [47].
4.4. CD6
There is also a genetic impact on Th17 cells that are supposed to
induce inﬂammation in the CNS and are probably followed by theother immune cells mainly Th1 cells. A metaanalysis revealed evi-
dence that rs17824933 associated to the CD6 gene is a risk locus
for MS [50]. CD6 affects T cell regulation and adhesion to endothe-
lium of leukocytes [51]. Recently an upregulation of CD6 in Th17
cells compared to Th1 cells from MS patients has been shown,
explaining in part the better adhesion and transmission of the
blood–brain barrier by Th17 cells [52].
5. Genes affecting different cells of the immune system
5.1. CLEC16A
An association of rs6498169 located in the C-type lectin domain
family 16 member A (CLEC16A) was suggested ﬁrst in the large
association study of the IMSGC and reached genome wide signiﬁ-
cance after combination of the data with an Australian sample
[24,53]. Meanwhile this SNP was replicated in several studies
and other SNPs located in an interval of about 50 kb in intron 19
of the CLEC16A gene, e.g., rs725613 were identiﬁed and replicated
[31,48,53–55]. CLEC16A is mainly expressed in cells of the immune
system, e.g., in B- and T- lymphocytes, Natural Killer cells and den-
dritic cells, however, its precise function is unknown. In general, C-
type lectins act as pattern recognition receptors for recognition of
pathogens like Mycobacterium tuberculosis and HIV-1 by dendritic
cells and speciﬁc induce signaling pathways that initiate immune
responses against pathogens [56,57].
5.2. VAV1
An association of rs2546133-rs2617822 haplotypes in the ﬁrst
VAV1 intron with experimental allergic encephalomyelitis (EAE)
and MS in an analysis of seven human cohorts has been recently
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with increased VAV1 mRNA expression in PBMCs. Moreover VAV1
expression was increased in individuals with MS and correlated
with tumor necrosis factor and interferon-c expression in periph-
eral blood and cerebrospinal ﬂuid cells [58]. VAV proteins function
as guanine nucleotide exchange factors for Rho family GTPases that
regulate the survival, proliferation and differentiation of lympho-
cytes [59,60]. In a genome wide association study we reported re-
cently suggestive evidence for association of VAV2 with MS
supporting the role of VAV proteins in autoimmunity of the CNS
[61].
6. Genes involved in tumor necrosis factor (TNF) signaling
TNF-a is increased in MS-lesions and levels in cerebrospinal
ﬂuid correlate with clinical deterioration [62]. However, treatment
with anti-TNF antibodies or with a TNFR1–IgG1 fusion protein
leads to clinical exacerbation of MS with increased rate and sever-
ity of relapses. This unexpected way of action may be due to en-
hanced antigen presenting cell function, increased T-cell receptor
signaling, decrease apoptosis of potentially autoreactive T-cells or
induction of the proinﬂammatory cytokines including IFN-c [63].
Two genes coding for TNF receptors have been shown to be associ-
ated MS.
Interestingly tumor necrosis factor receptor superfamily mem-
ber 1A gene (TNFRSF1A), encoding TNF receptor 1 (TNFR1) had
previously been associated with tumor necrosis factor-associated
periodic syndrome (TRAPS), an autoimmune disease characterized
by recurrent fever, abdominal pain, arthralgia, myalgia and cutane-
ous inﬂammation [64]. A metaanalysis revealed a link between the
TNFRSF1A locus and susceptibility to MS of a high-frequency poly-
morphism of modest effect (rs1800693, OR = 1.20) and a low-fre-
quency polymorphism of stronger effect (rs4149584) [50].
A large genome wide association study identiﬁed risk-associ-
ated SNPs upstream of CD40 (TNFRS5), another member of the tu-
mor necrosis factor receptor superfamily [49]. Lately the
predisposing effect on MS for a functional polymorphism located
in small distance from the start codon of the CD40 gene,
rs1883832, was replicated in a Spanish sample [65]. Interestingly,
rs1883832 C seems to be protective in MS, although it has been
associated with an increased risk of Graves’ disease and rheuma-
toid arthritis [49]. CD40 is expressed as a costimulatory molecule
on B cells, dendritic cells, macrophages and microglia and together
with its ligand, CD40L, which is expressed on activated CD4+
T-helper cells, an important regulator of humoral and cellular
immunity [66].
7. Genes affecting interferon metabolism
Two interferon regulatory factors and a Jak kinase involved in
interferon biology have been shown to be linked with MS suscep-
tibility. As interferon-b is the most common treatment of MS with,
however, an unclear mechanism of action, these genes are not only
interesting in the context of MS pathophysiology, but also in phar-
macogenetics and treatment response.
7.1. IRF5
Two SNPs and a 5 bp insertion–deletion polymorphism located
in the promoter and ﬁrst intron of the interferon regulatory factor
5 (IRF5) gene have been shown to be associated with MS when the
data from two case-control cohorts from Spain and Sweden, and a
set of MS trio families from Finland were combined [67]. Like the
genes mentioned before IRF5 is involved in the immune response,
as it regulates the toll-like receptor (TLR) dependent activation ofinﬂammatory cytokines [68]. IRF5 is expressed mainly in immune
cells, i.e., dendritic cells, monocytes and B cells, but not in thymus
tissue. In most other cell types like muscle or prostate cells IRF5 is
low expressed, but is induced by viral infection and type I interfer-
ons (IFN) like IFN-b that is a standard treatment of MS [69].
7.2. IRF8
A susceptibility allele near IRF8 that encodes a transcription fac-
tor known to function in type I interferon signaling, leads to higher
mRNA expression of IFN-response pathway genes in MS patients
[50]. Upon different functions IRF8 is involved in B-cell germinal
center development [70].
7.3. TYK 2
Another gene involved in the mechanisms of action of IFN is the
tyrosine kinase 2 (TYK2). Rs34536443 within this gene was re-
ported to be associated with MS susceptibility and replicated re-
cently [71,72]. As a JAK kinase TYK2 activates the expression of
IFN-regulated genes by the JAK/STAT pathway. Moreover it is in-
volved in different cytokine pathways (IL-6, IL-10, IL-12, IL-23
interferon lambda) [72–75]. In TYK2GC carriers TYK2-related cyto-
kine pathways experience a global decrease in activity. Addition-
ally TYK2GC carriers showed increased Th2 response compared to
TYK2GG carriers [76].
8. Vitamin D metabolism
The intensity of sunlight is an important environmental factor
inﬂuencing MS risk, this may be at least in part due to light depen-
dent production of active vitamin D in the skin. The involvement of
active 1,25 dihydroxy-vitamin D in the pathogenesis of MS is sup-
ported by an genetic impact of CYP27B1 that encodes the enzyme
25-hydroxyvitamin D-1 alpha hydroxylase, which hydroxylates
25-hydroxyvitamin D into the bioactive form. It is located within
a cluster of genes on chromosome 12q13-14 that was identiﬁed
by the ANZgene GWAS as potentially associated with MS [49].
Bioactive 1,25(OH)2vitamin D modulates innate immunity and reg-
ulates adaptive immunity, tolerance and B-cell homeostasis
[77,78]. Moreover activated T cells can be directed toward a T help-
er type 2 anti-inﬂammatory phenotype by 1,25(OH)2vitamin D
[79].
9. Genes involved in neuronal surveillance and repair
Of interest, two genes not involved in the immune system but
neuronal repair mechanisms are possibly associated with MS.
These genes may inﬂuence neurodegeneration and the potential
of remyelination of lesions. The involvement of these genes gives
a hint to a disturbance of repair mechanisms additional to autoim-
mune processes in MS.
9.1. KIF1b
The inﬂuence of the kinesin family member 1b (KIF1b) gene on
MS risk is still controversial. In 2008, rs10492972[C] located in the
KIF1b gene was reported to be associated with MS with an odds ra-
tio of 1.35 (P = 2.5  1010) [80]. On the contrary, two large scale
studies failed to replicate this effect [81,82]. The potential func-
tional role of the kinesin motor protein KIF1b is interesting, as it
is not involved in immunity like the other genes mentioned above,
but in myelination. It is involved in the axonal transport of mito-
chondria and synaptic vesicles, required for the localization of
myelin basic protein mRNA to processes of myelinating oligoden-
S. Nischwitz et al. / FEBS Letters 585 (2011) 3789–3797 3793drocytes in zebraﬁsh and required for outgrowth of axons in the
peripheral and central nervous systems [83]. However, it is associ-
ation with MS has not been validated so far.
9.2. GPC5
In the so far largest genome wide association study published
rs9523762 mapping in the GPC5 gene was newly identiﬁed and
association was replicated in a Spanish independent cohort (G al-
lele, odds ratio = 1.23) [84,85]. Glypican proteoglycan 5 (GPC5) is
a heparan sulfate proteoglycan core protein expressed on the cell
surface. It is rather involved in repair mechanism than in immune
processes, but glypicans are also found in dense networks in active
MS plaques, where they may be involved in sequestering pro-
inﬂammatory chemokines [86]. GPC5 is highly conserved and like
the other glypicans important for growth and differentiation pro-
cesses in different tissues including a role in neuronal connectivity
and regulation of synapse formation in fetal mammals [87]. Its
expression in adults, however, is limited to the brain, where it
may affect neuronal growth and repair by interaction with differ-
ent growth factors [88,89].Fig. 2. Strategies to discover genes important in MS pathogenesis.10. Risk scores and pathways
As all of these genetic risk factors contribute only a small
amount to MS susceptibility, a weighted risk score including 16
susceptibility alleles (2 HLA genes and 14 non-HLA genes) acquired
from a metaanalysis was developed [90]. These alleles were
weighted differentially due to their anticipated contribution, with
the highest weight of rs3135388 within HLA-DRB1 (30.3% of total
weight). The second included HLA locus rs2523393 within HLA-B
gene had 7.4% of total weight. HLA-A loci were not included. The
highest estimated inﬂuence of a non-HLA gene had rs2300747
within CD58 (7.8% of total weight). Well established SNPs within
IL2RA, IL7RA, CLEC16A were equally integrated as less replicated
possible risk factors, e.g., ZMIZ1. In further analysis also environ-
mental risk factors, in particular smoking and anti-EBV antibody ti-
ters were implied. After inclusion of sex into the score it modestly
predicts MS risk (C statistic for the model is 0.721), but not the con-
version of clinically isolated syndrome to MS [90]. Therefore it is
not yet useful for clinical practice.
Taking into account the small effects demonstrated by non-HLA
genes with respect to MS susceptibility, their knowledge seems
more relevant to learn about pathophysiology of MS than to devel-
op risk scores for susceptibility.
In an approach to identify pathophysiologically relevant com-
mon variants, modestly associated (P < 104) genes identiﬁed in
large GWAs were set into context by network-based pathway anal-
ysis. This analysis revealed 346 signiﬁcant modules, of which HLA
genes were included in the most signiﬁcant node. As expected sev-
eral pathways involved in the immune system and cell adhesion
were identiﬁed, but interestingly neural pathways associated with
axon guidance and neurogenesis, too [91]. Pathway analysis may
offer a new way to identify genes involved in the pathophysiology
of MS and to explain the heterogeneity of clinical symptoms. In
context of previously reported elevated glutamate levels in the
brain of MS patients the extent of genomic control over glutamate
levels was lately analyzed. The combination of a genome-wide
association analysis using brain glutamate concentration as a
quantitative trait and a protein interaction network to ﬁnd associ-
ated genes within the same pathway revealed rs794185, a non-
coding single nucleotide polymorphismwithin the gene sulphatase
modifying factor 1 as top marker and a module composed of 70
genes involved in glutamate biology. A higher number of associ-
ated alleles within genes in this module correlated with higherbrain levels of glutamate, greater decreases in N-acetylaspartate
and in brain volume indicating more severe neurodegeneration
[92].
Recently, epigenetic inﬂuences on disease susceptibility are
widely discussed. As monozygotic twins have a risk of 25% to de-
velop MS, if the other one is affected, environmental factors and/
or epigenetic mechanisms seem to be responsible [93]. In a ﬁrst ap-
proach the genome, epigenome and transcriptome of CD4+ T-cells
from a pair of monozygotic twins – one suffering from MS, the
other one unaffected – was analyzed. However, no relevant differ-
ences could be found [94].
11. Pharmacogenetic aspects
In the last years the genetic impact on the clinical response to
immunomodulatory drugs mainly interferon beta (IFN-b) that are
the most widely used disease modifying drugs for treatment of
MS, has been evaluated. Interestingly, some of the susceptibility
genes mentioned above affect also the response to IFN-b. A haplo-
type determined upregulation of IL-7RA by IFN-b has been recently
reported, possibly inﬂuencing the therapeutical effect [36]. Two
SNPs (rs10492503, rs9301789) within the GPC5 gene rank second
and third in an approach to discriminate responders and non
responders to IFN-b therapy and have been independently repli-
cated [95]. Two SNPs – IFNAR2 and ADAR – are closely related to
the IFN-b pathways. These SNPs were independently replicated
in a second study [96]. A relative large proportion of other SNPs
identiﬁed in these two studies are located within brain speciﬁc
genes. Two of these genes, COL25A1, coding for a brain speciﬁc
membrane bound collagen, and ERC2, involved in the regulation
of neurotransmitter release, have also been associated with the risk
of neurodegenerative diseases. Also GRIA3, coding for an AMPA
type glutamate receptor, NPA53, neuronal PAS domain protein 3,
and Cit coding for kinase on sites of postsynaptic sites of glutama-
tergic and GABAergic neurons seem to inﬂuence interferon re-
sponse in patients. In addition three more genes, ZFAT and
ZFHX4 both coding for zinc ﬁnger proteins and STARD13, coding
a GTPase activating enzyme, were reported in these studies. The
mechanism, however, remains unclear [97].
The development of neutralizing antibodies against IFN-b is one
of the main reasons for treatment failure. High titer of neutralizing
antibodies abolish the in vivo bioactivity of the drug and the treat-
ment effects with respect to clinical and paraclinical outcome
parameters [98]. According to current guidelines patients with
neutralizing antibodies do not beneﬁt from therapy and IFN-b ther-
apy is no longer recommended [99,100]. While formulation of the
drug has a proven impact on the development of NABs [97,101],
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Unfortunately IFN-b preparations that induce neutralizing antibod-
ies more frequently seem to be more effective to suppress clinical
and paraclinical disease activity in antibody negative patients
[102,103]. Therefore the predisposition to develop these antibodies
is of interest and may inﬂuence therapy decisions and test frequen-
cies. As the impact of genes on immune responses is well known, it
is likely that the formation of anti-IFN-b antibodies is inﬂuenced by
genetic factors. First results demonstrate, that HLA-DRB10401 or
HLADRB10408 allele carriers have a 5- and 14-fold increased risk
to develop antibodies to IFN-b [104]. Recently SNPs within and
outside the HLA locus have been identiﬁed to affect the immune
response against IFN-b [105].
Another drug widely used as therapy in relapsing remitting MS
patients is glatiramer acetate. To identify genetic markers that pre-
dict response to glatiramer acetate, two fractional cohorts of clin-
ical trials were genotyped for 61 single nucleotide
polymorphisms within 27 candidate genes. A signiﬁcant associa-
tion between glatiramer acetate response and a SNP in a T-cell
receptor beta variant was identiﬁed and replicated in the two inde-
pendent cohorts (odds ratio = 6.85). In one of the cohorts a variant
in the Cathepsin S gene was reported to be associated with drug re-
sponse (odds ratio = 11.59), but failed replication. Additionally
MBP, CD86, FAS, IL1R1 and IL12RB2, which maybe involved in gla-
tiramer acetate’s mode of action showed nominally signiﬁcance,
but did not withstand corrections [106].
So far, there are no studies on pharmacogenomics of natal-
izumab and other now upcoming monoclonal antibody therapies.
However, during therapy with natalizumab immunogenicity with
acquired neutralizing antibodies against natalizumab is a problem
similar to the therapy with interferons. A major problem, however,
is the increased risk for progressive multifocal leukoencephalopa-
thy (PML), a JC Virus induced disabling and sometimes lethal
encephalitis, during the therapy with natalizumab. Therefore stud-
ies addressing drug response, development of antibodies and a po-
tential genetic inﬂuence on the risk for PML are needed for
individualized treatment.12. Conclusion and outlook
In recent years both HLA-class I and -class II loci have been
shown to modify risk for MS susceptibility independently of
HLA-DRB11501, -DRB50101 in a positive (i.e., increasing risk)
or negative (i.e., decreasing risk/protecting) way and an increasing
number of susceptibility genes outside the HLA complex have been
identiﬁed.
As the non-HLA genes demonstrate only a low impact on sus-
ceptibility, they will probably not lead to a risk score or screening
for MS susceptibility in the next few years. However, their main
relevance is to point to new pathways in the pathogenesis of MS.
Most susceptibility genes are involved in the immune system sup-
porting an autoimmune aetiology of MS. The majority of the newly
identiﬁed SNPs are probably not causative, therefore sequencing
will be necessary to discover causal variants within the genes.
Association, however, is not sufﬁcient to prove involvement in
pathogenesis. Therefore importance of the variants has to be vali-
dated by functional studies.
Another important point is that polymorphisms identiﬁed so far
explain only part of the genetic variation. Most studies used micro-
arrays designed to detect SNPs with a minor allele frequency (MAF)
of P5%. Next generation microarrays have the power to detect
SNPs with a MAF P2.5%. Rare SNPs, however, are only detectable
by sequencing. Therefore the newly discovered non-HLA SNPs are
mostly common variants that have only low impact on MS suscep-
tibility. An alternative is, to look for rare variants that may demon-strate a stronger effect on MS susceptibility. A promising strategy
to identify rare variants may be to impute SNPs, e.g., from the
1000 Genomes Project that are in LD with the associated SNPs
and to validate results by sequencing. Other approaches combine
clinical parameters and a protein interaction network with the
evaluation of a genome wide association analysis to ﬁnd associated
genes [92]. The most promising strategy to identify so far unknown
rare variants is to sequence the whole genome of a sufﬁcient num-
ber of MS patients in comparison to matched controls. Due to the
extremely fast development in this ﬁeld, the latter may be possible
in the near future.
Besides the discovery of new SNPs another strategy to identify
new pathways is to look for gene by gene interactions – epistasis.
The analysis of genome-wide association data is usually done just
testing each polymorphism, usually SNPs, by itself thus performing
a number of tests equal to the total number of SNPs. This has pro-
ven to be successful in many ways, but maybe less successful than
occasionally expected and hoped for. A logically following ap-
proach is the study of epistasis, which may uncover more heritabil-
ity explained than single locus analysis. This is not very often done,
as it is computationally expensive, for example all possible two-
way combinations in a sample of 2 million SNPs (as in an imputed
data-set) make up roughly 2  1012 combinations. Several imple-
mentations of this type of analysis in useful time exist [107,108].
Genome-wide association studies in complex disorders such as
MS require very large patient numbers to uncover new risk loci. In
contrast, genome-wide gene expression studies require smaller
sample sizes to uncover genes that are differentially expressed
and possibly the underlying mechanisms, but are much more difﬁ-
cult with respect to sample collection. These studies are also highly
suitable for studying drug responders and non-responders or other
clinical subgroups. Strategies to discover genes important in MS
pathogenesis are summarized in Fig. 2.
A combination of both genome-wide association studies and
differential gene expression proﬁling under inclusion of HLA-typ-
ing may increase the likelihood to identify new disease relevant
biomarkers [109,110]. Stratiﬁcation for HLA-class II and -class I
types is of interest as different HLA loci have consistently been
identiﬁed as MS susceptibility genes and several studies suggest
an impact on disease course and severity. In particular, studies per-
formed in clinically well-characterized patient cohorts, including
MRI phenotype, treatment responsiveness, antibody proﬁle and
lifestyle factors may further increase the number and speciﬁcity
of genes and other factors involved in the pathogenesis and disease
course of MS.
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